BioSpace

CSL strikes up to $1.6B deal with Alentis for autoimmune drug with broad potential

CSL will co-develop and co-promote Alentis Therapeutics' anti-claudin-1 therapy lixudebart for kidney and liver conditions, including primary sclerosing cholangitis and a systemic autoimmune disease characterized by small blood vessel inflammation.

By BioSpace

1 min read
CSL strikes up to $1.6B deal with Alentis for autoimmune drug with broad potential
CSL strikes up to $1.6B deal with Alentis for autoimmune drug with broad potential

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights